Pulse Biosciences (PLSE) EBT Margin (2021 - 2026)

Pulse Biosciences (PLSE) posted quarterly EBT Margin of 34838.37% for Q3 2025, down 559.63% quarter-over-quarter from 5281.51% in Q2 2022.

Pulse Biosciences (PLSE) EBT Margin (2021 - 2026) Analysis & Trends

Pulse Biosciences' EBT Margin history runs 3 years deep, the most recent figure standing at 34838.37% for Q3 2025.

In Q3 2025, EBT Margin changed N/A year-over-year to 34838.37%; the TTM figure through Sep 2025 stood at 25437.21% (changed N/A YoY), while the FY2022 annual figure was 8357.86%, down 381071.0% from the prior year.
EBT Margin for Q3 2025 stood at 34838.37%, down from 5281.51% in the prior quarter.
The five-year high for EBT Margin was 1872.03% in Q4 2021, with the low at 34838.37% in Q3 2025.
The 3-year median for EBT Margin is 3890.32% (2022), against an average of 9696.93%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Intuitive Surgical	135.11 Bn	129.89 Bn	1.96 Bn	36.46%
2	Becton Dickinson	52.56 Bn	51.69 Bn	2.32 Bn	11.12%
3	Alcon	35.75 Bn	34.40 Bn	1.68 Bn	-1.63%
4	Resmed	34.02 Bn	32.55 Bn	861.22 Mn	32.40%
5	Medline	29.09 Bn	26.41 Bn	2.22 Bn	3.06%
6	West Pharmaceutical Services	24.92 Bn	24.49 Bn	329.20 Mn	20.65%
7	Solventum	15.30 Bn	14.90 Bn	1.29 Bn	4.89%
8	Cooper Companies	14.83 Bn	14.69 Bn	735.40 Mn	-4.48%
9	Baxter International	13.66 Bn	11.51 Bn	1.03 Bn	5.34%
10	Pulse Biosciences	3.43 Bn	3.43 Bn	161,000.00	-5,684.79%

Download Data